Latest Breaking News On - Jiong lan - Page 1 : comparemela.com

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

Qiang luLili tangFubo xieSiyuan leFusheng zhouJinmin renDragan cicicGenfleet therapeutics incSellas life sciences groupJiong lanGenfleet therapeuticsCell cycleN vivoProtein expression

GFH009: Potent, Selective CDK9 Inhibitor for Hematologic Cancer

GFH009: Potent, Selective CDK9 Inhibitor for Hematologic Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Jinmin renDragan cicicLili tangFubo xieFusheng zhouQiang luSiyuan leSellas life sciences groupGenfleet therapeutics incOncotarget volumeJiong lanGenfleet therapeutics

GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX® (cetuximab)

/PRNewswire/ GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced.

Yu wangUnited statesYun zengAmerican society of clinical oncologyGenfleet therapeuticsClinical oncologyAnnual meetingChief medical officerJiong lanChief executive officerFleet therapeutics

GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)

/PRNewswire/ GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food.

Yu wangNova science pub incUniversity of colorado anschutz medical campusDrug administrationChina hypertensionGenfleet therapeuticsColorado anschutz medicalChief medical officerJiong lanChief executive officerArterial diseaseRisk factor profileClinical featuresCurr atheroscler repChina hypertension surveyIntj cardio

GenFleet Receives CTAs Approval for Two Phase II Combination Studies of TGF-β R1 Inhibitor (GFH018) with PD-1 Inhibitor

/PRNewswire/ GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China s.

Yu wangUnited statesChina national medical products administrationChina hospital of sichuan universityUnion medical college hospitalSun yat sen university cancer centerGenfleet therapeuticsNational medical products administrationClinical trial applicationsChina taiwanChief medical officerJiong lanChief executive officerOriental hospitalWest china hospitalSichuan university